PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

The EMA CHMP has determined that the proposed Artificial Intelligence-Based Measurement of Non-alcoholic Steatohepatitis Histology ... inclusion in clinical phase 2 and phase 3 trials in MASH ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China ... from simple fatty liver to non-alcoholic steatohepatitis (NASH) and can progress to fibrosis ...

Table 1. Studies investigating the results of treatments through conventional light microscopy histology in human nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. FFA: Free fatty ...

Experimentally, the expression of UCP-2 is upregulated in animal models of steatohepatitis ... Portal inflammation: none or mild. Grade 2, moderate Steatosis: any degree; usually mixed ...